Bayer Aktien Stock Price, News & Analysis

Bayer (OTC: BAYRY) launched the “Highlights REAL” campaign with former quarterback Tony Romo and his father Ramiro to raise awareness of advanced prostate cancer and treatment management. The campaign encourages patients and caregivers to discuss treatment options, including NUBEQA (darolutamide), with their doctor and directs audiences to HighlightsREAL.com. Tony and Ramiro were compensated and are not NUBEQA patients. The release includes important safety information and directs readers to full prescribing information.

Bayer (OTC:BAYRY) announced an investment of more than $45 million CAD to build a canola innovation centre in Winnipeg, Manitoba to strengthen canola R&D in Canada. The centre will support seed development for canola, camelina and winter canola with work on trait integration, yield trial seed processing and seed quality analysis.

Design begins in 2026 with the facility expected to be operational by the end of 2028. The site will consolidate some breeding and seed generation activities while existing Smartpark and Carman sites maintain early breeding workflows and multi-crop nursery operations.

Bayer (OTC:BAYRY) will present main results and a prespecified subgroup analysis from the global Phase III OCEANIC-STROKE trial of asundexian, an investigational once-daily oral Factor XIa inhibitor, during two late-breaking sessions at the International Stroke Conference 2026 in New Orleans on February 4-6, 2026.

The multicenter, randomized, placebo-controlled, double-blind study enrolled >12,300 patients and, according to Bayer, met its primary efficacy and safety endpoints in November 2025.

Bayer (OTC: BAYRY) and Vanderbilt University Medical Center agreed a strategic five-year collaboration to accelerate discovery and development of therapies from target identification through Investigational New Drug (IND) application.

The partnership initially targets cardiovascular and kidney diseases, and will leverage VUMC’s BioVU DNA and plasma datasets and VUMC clinical/preclinical expertise combined with Bayer’s drug discovery and translational capabilities to enable data-driven insights and speed development of precision medicines.

Bayer (OTC:BAYRY) outlined an accelerated Pharmaceuticals growth strategy at the J.P. Morgan Healthcare Conference focusing on oncology, cardiology, neurology, immunology, women’s health, and molecular imaging.

Key facts: five pivotal approvals in 2025; Phase III OCEANIC-STROKE met primary endpoints for asundexian; finerenone (Kerendia) approved in US and Japan for HF with LVEF ≥40% with other markets under review; Nubeqa has treated over 200,000 patients; FDA granted accelerated approval to Hyrnuo (sevabertinib). Bayer launched CGT, gene therapy and imaging programs and acquired two investigational radiotracers to enter molecular imaging.

Bayer (OTC: BAYRY) partnered with actress Gabrielle Union-Wade on the “Life Doesn’t Stop for a Hot Flash” campaign to raise awareness of treatment options for moderate to severe hot flashes due to menopause. The campaign highlights Lynkuet (elinzanetant) 60 mg, a hormone-free, FDA-approved prescription treatment for moderate to severe hot flashes, approved in October 2025, and will run across digital channels and streaming services encouraging conversations with healthcare providers. Safety information and prescribing guidance, including liver monitoring and pregnancy warnings, are included.

Bayer (OTC:BAYRY) agreed to acquire two investigational molecular imaging tracers from Attralus: AT-01 (124-iodine evuzamitide) and AT-05 (PAR-peptide + technetium-99m). AT-01 is in Phase III and holds FDA Breakthrough Therapy plus Orphan Drug designations (U.S. and EU); AT-05 is in Phase I. The acquisition expands Bayer into diagnostic tracers for cardiac and systemic amyloidosis, a disease estimated to affect ~400,000 people globally, and complements Bayer’s radiology and cardiovascular portfolio. Financial terms were not disclosed. Attralus will refocus on its therapeutic programs including AT-02 in Phase II.

Bayer (OTC: BAYRY) and Soufflé Therapeutics announced a strategic collaboration and global license to develop a cell-selective, heart-targeted siRNA therapy for a form of dilated cardiomyopathy affecting a rare subset of patients. The partnership combines Soufflé’s proprietary ligand and siRNA engineering to deliver therapies directly to cardiomyocytes with Bayer’s cardiovascular development expertise. The program aims to reduce off-target effects and dosing frequency by improving targeted delivery to heart muscle cells. Financial terms and clinical timelines were not disclosed.

Bayer (OTC:BAYRY) will present at the 44th J.P. Morgan Healthcare Conference in San Francisco, held January 12–15, 2026.

Stefan Oelrich, Member of the Board of Management and President of Bayer’s Pharmaceuticals Division, will deliver an update on Bayer’s pharmaceutical growth strategy and pipeline advancements on Tuesday, January 13, 2026, 11:15–11:55 PST. The presentation will be available via live webcast and later posted with related materials on Bayer's website.